[ {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RABZCi5tO-IHsWB5zOWOTt1FR5exwbMx9INlJHLOfNvMY",
    "@type" : [ "http://www.nanopub.org/nschema#Nanopublication" ],
    "http://www.nanopub.org/nschema#hasAssertion" : [ {
      "@id" : "http://purl.org/np/RABZCi5tO-IHsWB5zOWOTt1FR5exwbMx9INlJHLOfNvMY#assertion"
    } ],
    "http://www.nanopub.org/nschema#hasProvenance" : [ {
      "@id" : "http://purl.org/np/RABZCi5tO-IHsWB5zOWOTt1FR5exwbMx9INlJHLOfNvMY#provenance"
    } ],
    "http://www.nanopub.org/nschema#hasPublicationInfo" : [ {
      "@id" : "http://purl.org/np/RABZCi5tO-IHsWB5zOWOTt1FR5exwbMx9INlJHLOfNvMY#pubinfo"
    } ]
  } ],
  "@id" : "http://purl.org/np/RABZCi5tO-IHsWB5zOWOTt1FR5exwbMx9INlJHLOfNvMY#Head"
}, {
  "@graph" : [ {
    "@id" : "http://purl.obolibrary.org/obo/DOID_10763",
    "https://w3id.org/biolink/vocab/category" : [ {
      "@id" : "https://w3id.org/biolink/vocab/Disease"
    } ]
  }, {
    "@id" : "http://purl.org/np/RABZCi5tO-IHsWB5zOWOTt1FR5exwbMx9INlJHLOfNvMY#association",
    "@type" : [ "http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement" ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#object" : [ {
      "@id" : "http://purl.obolibrary.org/obo/DOID_10763"
    } ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate" : [ {
      "@id" : "https://w3id.org/biolink/vocab/treats"
    } ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#subject" : [ {
      "@id" : "https://identifiers.org/drugbank:DB01197"
    } ],
    "http://www.w3.org/2000/01/rdf-schema#label" : [ {
      "@value" : "captopril tablets usp are indicated for the treatment of hypertension hypertension in using captopril consideration should be given to the risk of neutropenia agranulocytosis see warnings captopril may be used as initial therapy for patients with normal renal function in whom the risk is relatively low in patients with impaired renal function particularly those with collagen vascular disease captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs or have failed to respond satisfactorily to drug combinations captopril is effective alone and in combination with other antihypertensive agents especially thiazide type diuretics the blood pressure lowering effects of captopril and thiazides are approximately additive captopril tablets are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis the beneficial effect of captopril in heart failure does not require the presence of digitalis however most controlled clinical trial experience with captopril has been in patients receiving digitalis as well as diuretic treatment heart failure captopril tablets are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction 4 and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients left ventricular dysfunction after myocardial infarction captopril tablets are indicated for the treatment of diabetic nephropathy proteinuria 5 mg day in patients with type i insulin dependent diabetes mellitus and retinopathy captopril tablets decreases the rate of progression of renal insufficiency and development of serious adverse clinical outcomes death or need for renal transplantation or dialysis diabetic nephropathy in considering use of captopril tablets it should be noted that in controlled trials ace inhibitors have an effect on blood pressure that is less in black patients than in non blacks in addition ace inhibitors for which adequate data are available cause a higher rate of angioedema in black than in non black patients see warnings angioedema"
    } ],
    "https://w3id.org/biolink/vocab/association_type" : [ {
      "@id" : "https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation"
    } ],
    "https://w3id.org/biolink/vocab/provided_by" : [ {
      "@id" : "https://w3id.org/um/NeuroDKG"
    } ],
    "https://w3id.org/biolink/vocab/relation" : [ {
      "@id" : "https://schema.org/TreatmentIndication"
    } ]
  }, {
    "@id" : "https://identifiers.org/drugbank:DB01197",
    "https://w3id.org/biolink/vocab/category" : [ {
      "@id" : "https://w3id.org/biolink/vocab/Drug"
    } ]
  } ],
  "@id" : "http://purl.org/np/RABZCi5tO-IHsWB5zOWOTt1FR5exwbMx9INlJHLOfNvMY#assertion"
}, {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RABZCi5tO-IHsWB5zOWOTt1FR5exwbMx9INlJHLOfNvMY#assertion",
    "http://www.w3.org/ns/prov#wasAttributedTo" : [ {
      "@id" : "https://orcid.org/0000-0002-1468-3557"
    } ]
  } ],
  "@id" : "http://purl.org/np/RABZCi5tO-IHsWB5zOWOTt1FR5exwbMx9INlJHLOfNvMY#provenance"
}, {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RABZCi5tO-IHsWB5zOWOTt1FR5exwbMx9INlJHLOfNvMY",
    "http://purl.org/dc/terms/created" : [ {
      "@type" : "http://www.w3.org/2001/XMLSchema#dateTime",
      "@value" : "2021-06-15T18:41:02.353+02:00"
    } ],
    "http://purl.org/dc/terms/creator" : [ {
      "@id" : "https://orcid.org/0000-0002-1468-3557"
    } ],
    "https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate" : [ {
      "@id" : "http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM"
    } ],
    "https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate" : [ {
      "@id" : "http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM"
    } ],
    "https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate" : [ {
      "@id" : "http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs"
    } ]
  }, {
    "@id" : "http://purl.org/np/RABZCi5tO-IHsWB5zOWOTt1FR5exwbMx9INlJHLOfNvMY#sig",
    "http://purl.org/nanopub/x/hasAlgorithm" : [ {
      "@value" : "RSA"
    } ],
    "http://purl.org/nanopub/x/hasPublicKey" : [ {
      "@value" : "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB"
    } ],
    "http://purl.org/nanopub/x/hasSignature" : [ {
      "@value" : "bWWrGbKtB6HYf1czerCGKzKzIIHArTeTGbbuIjEAvoUfE5c5eu6oAfHpVUBqDXuzg//eiRU/hdoI+bPAOwuGDSEIOsJiGJCne59r3GSsrMZIsdcPVkowBly9Aggjbgv6T3KiFlbeflqCwvxoEa1SGwoAiMP0/CBz05CZGmo/sl4="
    } ],
    "http://purl.org/nanopub/x/hasSignatureTarget" : [ {
      "@id" : "http://purl.org/np/RABZCi5tO-IHsWB5zOWOTt1FR5exwbMx9INlJHLOfNvMY"
    } ]
  } ],
  "@id" : "http://purl.org/np/RABZCi5tO-IHsWB5zOWOTt1FR5exwbMx9INlJHLOfNvMY#pubinfo"
} ]